BSGM - BioSig Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.65
-0.60 (-6.49%)
As of 12:38PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close9.25
Open9.03
Bid8.86 x 900
Ask8.89 x 1100
Day's Range8.59 - 9.25
52 Week Range3.50 - 9.97
Volume146,474
Avg. Volume191,393
Market Cap181.169M
Beta (3Y Monthly)0.43
PE Ratio (TTM)N/A
EPS (TTM)-1.32
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    BioSig Technologies Issues June 2019 Shareholder Letter

    BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company has issued their June 2019 Shareholder Letter, highlighting successful patient cases using PURE EP™ System at three different medical centers, strengthening of patent portfolio and publication strategy, inclusion on the Russell 3000® Index, and other milestones moving toward commercialization.

  • GlobeNewswire14 days ago

    BioSig Technologies Set to Join Russell 3000® Index

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the company is set to join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, 2019 according to a preliminary list of additions posted June 7, 2019. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell indexes are part of FTSE Russell, a leading global index provider.  For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

  • GlobeNewswire18 days ago

    BioSig Allowed a U.S. Patent for PURE EP™ Simulator

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the U.S. Patent & Trademark Office allowed a U.S. patent application covering its electrophysiology simulator. The patent application number 15/103,278 entitled, "Systems and Methods For Evaluation of Electrophysiology Systems" was filed on June 9, 2016.  The patent has not yet been published.

  • GlobeNewswire21 days ago

    BioSig Technologies Receives $4.6 Million in Cash Warrant and Option Exercises

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that it received a total of $4.6 million in warrant and option exercises in Q1 and Q2 2019. The Company intends to use the proceeds from these cash exercises to support clinical activities. The Company is in a process of receiving 15 new units of PURE EP™ System, its novel signal acquisition and processing technology, from our manufacturer partner, Minnetronix™ Medical, to be used in Q3 2019.  These new systems will be evaluated by medical centers of excellence in the U.S., which are intended to support our sales and marketing activities going forward.

  • GlobeNewswire25 days ago

    BioSig Technologies to Present at the 9th Annual LD Micro Invitational

    Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc., will do a presentation on the Company’s recent progress, including successful clinical experience at the Texas Cardiac Arrhythmia Institute in Austin, TX, Greenville Memorial Hospital in Greenville, SC and Indiana University School of Medicine, BioSig’s first participation in the Heart Rhythm Society’s 40th Annual Scientific Sessions on May 8-11, 2019 at Moscone Center in San Francisco, CA and recent additions to the Company’s Board of Directors and Advisory Board. Mr. Londoner will also discuss the Company’s progress with the global IP strategy.

  • GlobeNewswirelast month

    BioSig Allowed First Key US Patent Claims for its PURE EP™ System

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the US Patent Office allowed 33 patent claims covering its PURE EP™ System. The patent application number 16/271,462 entitled "System and Methods to Visually Align Signals Using Delay," was filed on May 9, 2018 and subject to an accelerated Track One patent application filed on February 8, 2019.  The patent has not yet been published.

  • GlobeNewswirelast month

    Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors - Corrected Version

    Jerome (“Jerry”) Zeldis, M.D., Ph.D brings extensive life sciences experience gained primarily through his career at Celgene, Inc. He previously served as Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation (CELG), a publicly traded, fully integrated biopharmaceutical company, where he was employed for nearly 20 years, starting in 1997. Celgene Corporation’s Board of Directors and shareholders recently approved an offer to be acquired by Bristol Myers-Squibb (BMY) in a cash and stock deal valued at $74 billion at the time of the offer. “I am very pleased with the progress that has occurred from the time I left the Board until now,” commented Dr. Zeldis.

  • GlobeNewswirelast month

    Dr. Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors

    Jerome (“Jerry”) Zeldis, M.D., Ph.D brings extensive life sciences experience gained primarily through his career at Celgene, Inc. He previously served as Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation (CELG), a publicly traded, fully integrated biopharmaceutical company, where he was employed for nearly 20 years, starting in 1997. Celgene Corporation has been recently acquired by Bristol Myers-Squibb (BMY) in a cash and stock deal valued at $74 billion.

  • GlobeNewswire2 months ago

    BioSig Technologies Completes Patient Cases at Indiana University

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company conducted patient cases using the PURE EP(tm) System at Indiana University School of Medicine. The cases were conducted under the leadership of Prof. John M. Miller, M.D. and Dr. Mithilesh K. Das, MBBS.

  • GlobeNewswire2 months ago

    BioSig’s Manuscript Accepted to IEEE Engineering in Medicine and Biology Conference 2019

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address unmet needs for the electrophysiology (EP) marketplace, today announced that the manuscript entitled “Evaluation of Real Time Catheter Tissue Contact using Unipolar Intracardiac Signal Morphology” has been accepted to the 41st International Engineering in Medicine and Biology Conference (EMBC), to be held in Berlin, Germany from July 23 – 27, 2019. BioSig’s latest manuscript is discussing one of the most challenging objectives during EP studies – to achieve and maintain optimal contact between the catheter tip and myocardial tissue. The studies conducted by BioSig evaluated the morphology of unipolar intracardiac signals as an additional real time marker for contact evaluation and concluded that there was a correlation between the PR (for atria) and ST (for ventricles) segments and catheter contact force applied to the myocardium.

  • GlobeNewswire2 months ago

    BioSig To Participate at Heart Rhythm Society’s Scientific Sessions 2019

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address unmet needs for the electrophysiology (EP) marketplace, today announced that the Company will be exhibiting at the Heart Rhythm Society’s 40th Annual Scientific Sessions on May 8-11, 2019 at Moscone Center in San Francisco, CA. Previously, BioSig announced that it successfully conducted its first patient cases using PURE EP(tm) System at the Texas Cardiac Arrhythmia Institute in Austin, TX in February 2019 and Greenville Memorial Hospital in Greenville, SC in April 2019.

  • GlobeNewswire2 months ago

    BioSig Completes Successful Patient Cases at Greenville Memorial Hospital

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address unmet needs for the electrophysiology (EP) marketplace, today announced that the Company successfully conducted patient cases using PURE EP(tm) System at Greenville Memorial Hospital, part of Prisma Health System. PURE EP(tm) System is the Company’s FDA cleared proprietary electrocardiogram and intracardiac signal acquisition and amplification system.

  • GlobeNewswire2 months ago

    Frank J. Quintero Joins BioSig Technologies Advisory Board

    Santa Monica, CA, April 09, 2019 -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed.

  • GlobeNewswire3 months ago

    D.A. Wallach Joins BioSig Technologies Advisory Board

    Santa Monica, CA, March 26, 2019 -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed.

  • GlobeNewswire3 months ago

    BioSig Technologies Completes Private Placement

    BioSig Technologies, Inc. (NASDAQ: BSGM), today announced the closing of a private placement of the Company’s common stock for gross proceeds of approximately $8,620,506. The offering was exempt from registration under Section 4(a)(2) of the United States Securities Act of 1933, as amended, and Rule 506 of Regulation D promulgated by the U.S. Securities and Exchange Commission (“SEC”) thereunder. BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace (www.biosig.com).

  • ACCESSWIRE3 months ago

    LD Micro Virtual Conference Is Live, March 12th and 13th

    LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...

  • GlobeNewswire4 months ago

    BioSig Technologies to Present at the LD Micro Virtual Conference

    BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, announced today that they will be presenting at the second annual LD Micro Virtual Conference on Wednesday, March 13, 2019 at 2pm EST, 11am PT. Mr. Kenneth Londoner, Founder, Chairman & CEO of BioSig Technologies, Inc., will be giving the presentation and answering questions from investors.

  • GlobeNewswire4 months ago

    BioSig Technologies to Present at the 31st Annual ROTH Conference

    BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today that the Company will present at the 31st Annual ROTH Conference. The conference is being held at The Ritz Carlton, Laguna Niguel in Orange County, CA, on March 17-19, 2019.

  • GlobeNewswire4 months ago

    BioSig Appoints Barry Keenan as Vice President of Engineering

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company appointed Dr. Barry Keenan, Ph.D, MBA, PMP to head up BioSig’s advanced product development. Dr. Keenan brings to the Company over 20 years of experience in R&D, product development and commercialization and deep industry expertise in a range of sectors, including neuromodulation, deep brain stimulation, sensing, imaging and cardiac pacing.

  • GlobeNewswire4 months ago

    BioSig Announces Expansion of Engineering Team

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company appointed a Senior R&D Engineer and is working on further senior biomedical engineering hires to support BioSig’s growing manufacturing processes and advanced R&D activities. Mr. Fui Veavea brings to the Company over 29 years of manufacturing and engineering experience in a range of medical device sectors, including implantable class III devices, diabetes-monitoring and respiratory diagnostic systems.

  • GlobeNewswire4 months ago

    The Future Is Now; Med Tech That’s Changing Lives

    Investorideas.com, a leading investor news resource covering medical technology and healthcare stocks releases a snapshot looking at the rapid advancements happening in the med tech sector and how many of these “far off” projects are now on the verge of reality. BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, recently announced that the Company successfully conducted the first patient cases using PURE EP™ System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX.

  • GlobeNewswire4 months ago

    BioSig Announces Successful First-In-Human Use of PURE EP System

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company successfully conducted first patient cases using PURE EP(tm) System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX. The patient studies were conducted by Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.

  • GlobeNewswire4 months ago

    BioSig Technologies Inc. Issues 2019 Shareholder Letter

    BioSig Technologies, Inc. (BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company has issued their February 2019 letter to its shareholders, highlighting their recent uplisting to the Nasdaq Capital Market, commercialization efforts, their relationships with world renowned medical centers and strategic goals moving forward. Successfully raised a total of $13.5 million of capital, to finance upcoming operational milestones.

  • GlobeNewswire5 months ago

    BioSig Appoints John Kowalski to Lead Commercialization of PURE EP

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company has appointed Mr. John Kowalski as Vice President of Sales. Mr. Kowalski brings to the Company over 30 years of experience in medical device sales, including over 20 years at Biosense Webster, a Johnson & Johnson company.

  • Have Insiders Been Buying BioSig Technologies, Inc. (NASDAQ:BSGM) Shares?
    Simply Wall St.5 months ago

    Have Insiders Been Buying BioSig Technologies, Inc. (NASDAQ:BSGM) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...